Research Paper

Is Ep-CAM Expression a Diagnostic and Prognostic Biomarker for Colorectal Cancer? A Systematic Meta-Analysis

Susu Han, Shaoqi Zong, Qi Shi, Hongjia Li, Shanshan Liu, Wei Yang, Wen Li*, Fenggang Hou*

Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, 274 Zhijiang Road, Shanghai 200071, People’s Republic of China

ARTICLE INFO

Article history:
Received 13 April 2017
Received in revised form 11 May 2017
Accepted 22 May 2017
Available online 24 May 2017

Keywords:
Ep-CAM
Expression
CRC
Prognosis
Diagnosis
Biomarker

ABSTRACT

Background: Cancer stem cell (CSC) epithelial cell adhesion molecule (Ep-CAM) is frequently expressed in colorectal cancer (CRC). However, the clinical significance of Ep-CAM expression in CRC is not clear. This study evaluated whether Ep-CAM provided valuable insight as a molecular biomarker for CRC diagnosis and prognosis and the potential of Ep-CAM as a novel therapeutic target in CRC.

Methods: Publications were selected online using electronic databases. The pooled odds ratios (ORs) or hazard ratios (HRs) with their 95% confidence intervals (95% CIs), and the combined sensitivity, specificity, and area under the curve (AUC) were calculated and summarized.

Results: Eleven eligible articles published in English involving 4561 cases were analyzed in this study. Ep-CAM expression was significantly higher in CRC compared with normal controls, and its overexpression was negatively linked to tumor differentiation, tumor stage, vascular invasion, depth of tumor invasion, lymph node metastasis, distant metastasis, and tumor budding in CRC patients. The loss of Ep-CAM expression positively correlated with these characteristics. Multivariate analysis of loss of Ep-CAM expression correlated with a poor prognosis in disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). The pooled sensitivity, specificity, and AUC values of Ep-CAM expression in patients with CRC vs. normal controls were 0.93, 0.90, and 0.94, respectively.

Conclusions: The present findings suggest that Ep-CAM expression may be associated with CRC carcinogenesis, while the loss of Ep-CAM expression is correlated with the progression, metastasis, and poor prognosis of CRC. Ep-CAM expression may be a useful biomarker for the clinical diagnosis of CRC.

© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Colorectal cancer (CRC) is the fifth most frequent malignancy and the fifth leading cause of death in all human cancers in China (Chen et al., 2016). Global cancer statistics noted approximately 1.4 million new cases were clinically diagnosed with CRC in 2012 and an estimated 693,900 deaths occurred due to CRC worldwide (Torre et al., 2015). CRC is a major public health problem because approximately 50% of CRC cases develop metastasis and exhibit a poor survival rate despite advances in early detection and treatment (Aranda et al., 2015; Ferlay et al., 2015; Van Cutsem et al., 2010). Therefore, there is a need for a potential biological marker that allows early detection and predicts clinical prognosis of CRC.

A special subpopulation of cancer cells, known as cancer stem cells (CSCs), drive cancer progression. CSCs self-renew, uncontrollably proliferate, differentiate, and form the bulk of the tumor (Majumdar et al., 2012; Chandler and Lagasse, 2010). CSCs also regulate the development, progression, and metastasis of cancer (da Silva-Diz et al., 2016, Sampetean and Saya, 2013, Nguyen et al., 2012). Multiple studies reported evidence of CSCs in CRC (Patman, 2016; Zeuner et al., 2014). Epithelial cell adhesion molecule (Ep-CAM), also known as epithelial-specific antigen (ESA) or CD326, is a transmembrane glycoprotein cell adhesion molecule that is encoded by the Ep-CAM gene mapped to chromosomal region 4q (Balzar et al., 1999; Linnenbach et al., 1989). This cell adhesion molecule plays a key role in Ca2+-independent cell-to-cell adhesion (Litvinov et al., 1994). Ep-CAM correlates with cell proliferation, migration, invasion, motility, and signal transduction (Subramanian et al., 2015; Maetzel et al., 2009). Studies suggest that Ep-CAM is associated with epithelial-to-mesenchymal transition (EMT) and enhances tumor-initiating capacity (Gupta et al., 2009; Morel et al., 2008). Ep-CAM is overexpressed in many types of cancers, such as breast cancer, ovarian cancer, and head and neck squamous cell...
cancer (Moldenhauer et al., 2012). Some studies demonstrated that Ep-CAM overexpression was an unfavorable prognostic marker in breast cancer and gallbladder carcinoma (Varga et al., 2004; Gastl et al., 2000). Ep-CAM is a CSC marker, and it is frequently expressed or overexpressed in CRC (Dalerba et al., 2007; Mosolits et al., 2004). Ep-CAM is defined as a universal molecular marker for circulating tumor cell (CTC) detection, which is termed the “post-Ep-CAM era” (Nicolazzo et al., 2015; Raimondi et al., 2015). Therefore, it is important to investigate Ep-CAM further.

Some studies demonstrated inconsistent and controversial conclusions of Ep-CAM expression in CRC patients. For example, Kuhn et al. reported that Ep-CAM expression was not associated with tumor stage or grade (Kuhn et al., 2007). Gosens et al. reported that the loss of Ep-CAM expression was significantly associated with tumor grade and trended towards a correlation with tumor stage (Gosens et al., 2007). Therefore, the present study assessed whether Ep-CAM expression correlated with an increased risk of CRC vs. benign colonic lesions and normal controls. We also analyzed whether Ep-CAM overexpression or the loss of Ep-CAM expression was associated with the prognostic effect and clinicopathological features of CRC. Finally, we evaluated the use of Ep-CAM expression as a biomarker for the early diagnosis of CRC.

2. Materials and Methods

2.1. Literature Search

A comprehensive literature search (PubMed, EMBASE, EBSCO, Web of Science, and Cochrane Library databases) was performed to identify relevant publications on Ep-CAM expression in CRC patients prior to January 16th, 2017. The articles were identified using the following search terms and key words: ‘Ep-CAM’, ‘epithelial cell adhesion molecule’, ‘EpCAM’, ‘CD326’, ‘AG733’, ‘CO17-1A’, ‘EGP’, ‘K51-4’, ‘ESA’, ‘MOC31’, ‘BterEP4’, and ‘colorectal cancer’ ‘colorectal tumor’, ‘colorectal carcinoma’, ‘colorectal neoplasm’, ‘CRC’ and ‘expression’. The reference lists of the included articles were also screened to obtain other potential studies. This study was performed based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria (Moher et al., 2009) (Table S1).

2.2. Selection Criteria

Eligible studies were selected based on the following inclusion criteria: 1) patients were limited to a diagnosis of CRC; 2) articles were published in English with the full text; 3) Ep-CAM was considered as a positive expression, overexpression or a loss of the expression; 4) articles provided sufficient information to evaluate the correlation of Ep-CAM expression between CRC and nonmalignant controls; 5) articles provided sufficient data to assess the relationship of Ep-CAM expression with the clinicopathological characteristics of patients with CRC; and 6) the pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were extracted to evaluate the prognostic role when the data from the original papers were available. The most complete paper containing the most information was selected when authors published several articles using duplicated data.

2.3. Data Extraction

The following data were collected from eligible studies: first author’s surname, year of publication, country, ethnic population, age, detection method, clinical stage, staining patterns, cut-off values, Ep-CAM expression (overexpression or loss), expression frequency, number of cases and controls, survival data of multivariate analysis, and clinicopathological features. The clinicopathological characteristics included tumor differentiation (poor vs. well/moderate), tumor stage (3–4 vs. 1–2), vascular invasion (yes vs. no), depth of tumor invasion (pT3–4 vs. pT1–2), lymph node metastasis (yes vs. no), distant metastasis (yes vs. no), tumor budding (yes vs. no), and tumor location (colon vs. rectum). Loss of Ep-CAM expression consisted of complete and partial loss.

2.4. Statistical Analysis

Data were analyzed using Stata software (version 12.0, Stata Corporation, College Station, TX, USA). The combined odds ratios (ORs) and their 95% confidence intervals (95% CIs) were calculated to determine the relationship of Ep-CAM expression between CRC and nonmalignant controls. The associations of Ep-CAM overexpression or loss of Ep-CAM expression with the clinicopathological features of CRC were also calculated using pooled ORs with 95% CIs. The overall hazard ratios (HRs) with 95% CIs were used to determine the impact of Ep-CAM expression on the survival of CRC patients, if possible. Between-study heterogeneity was measured using the Cochran’s Q statistic (Zintzaras and Ioannidis, 2005). The random-effects model was used to increase the reliability of the results in the present analysis (heterogeneity: $P < 0.1$).

A sensitivity analysis was performed to determine the influence of one study on the results and heterogeneity via omission of a single study when the pooled results with greater than two studies had substantial heterogeneity ($P < 0.1$) (Higgins et al., 2003; Lau et al., 1997). Potential publication bias was assessed using Egger’s test for the results with greater than or equal to ten studies (Egger et al., 1997). The pooled sensitivity, specificity, and the summary receiver operator characteristic (SROC) curve (AUC) values were calculated and constructed according to the bivariate analysis to evaluate the performance of the diagnostic capacity of Ep-CAM expression to CRC in this study (Reitsma et al., 2005; Jones and Athanasiou, 2005).

3. Results

3.1. Characteristics of the Included Studies

Fig. 1 shows the detailed selection procedure used for the potential literature. The abovementioned inclusion criteria resulted in 11 eligible studies published in English from 2005 to 2016 (Kim et al., 2016; Chai et al., 2015; Zhou et al., 2015; Kim et al., 2014; Goossens-Beumer et al., 2014; Lugli et al., 2010; Paret et al., 2007; Kuhn et al., 2007; Gosens et al., 2007; Went et al., 2006; Karanikiotis et al., 2005) for the meta-analysis, which included 4103 CRC patients and 458 controls. Five studies of 331 patients with CRC and 458 controls analyzed the relationship of Ep-CAM expression between CRC and controls (Chai et al., 2015; Zhou et al., 2015; Paret et al., 2007; Kuhn et al., 2007; Karanikiotis et al., 2005). Six studies analyzed the correlation of Ep-CAM overexpression or loss with...
the clinicopathological characteristics of 3772 patients with CRC (Kim et al., 2016; Kim et al., 2014; Goossens-Beumer et al., 2014; Lugli et al., 2010; Gosens et al., 2007; Went et al., 2006). Two studies of 1031 CRC patients reported multivariate survival analyses of Ep-CAM expression (Kim et al., 2016; Goossens-Beumer et al., 2014). Ep-CAM expression was assessed on tissues using immunohistochemistry (IHC). Tables 1 and S2 present the main characteristics of all eligible studies.

### 3.2. Association of Ep-CAM Expression Between CRC and Controls

The overall OR from five studies of 331 patients with CRC and 402 normal controls demonstrated that the frequency of Ep-CAM expression in CRC was notably higher than in normal controls (OR = 96.70, 95% CI = 34.85–268.29, P < 0.001) (Fig. 2).

Two studies of 154 CRC patients and 56 benign colonic lesions revealed no significant difference between CRC and benign colonic lesions.

### Table 1

| First author                  | Country      | Ethnicity | Age | Method | Stage | Staining patterns | Cut off scores (positive) | Sample | Status | CRC N (E+) (%) | Benign N (E+) (%) | Normal N (E+) (%) | Clinicopathological features | MA-survival |
|------------------------------|--------------|-----------|-----|--------|-------|-------------------|---------------------------|--------|--------|----------------|---------------------|----------------------|-------------------------|-------------|
| Karanikiotis et al. (2005)   | Greece       | Caucasians| NA  | NA     | NA    | NA                | NA                        | Blood  | E      | 27 (96.3)      | 20 (0)              | NA                   | NA                      | NA          |
| Went et al. (2006)           | Iran         | Caucasians| 69.7| IHC    | NA    | M/C               | 70%                       | Tissue | High   | 1186 (97.7)    | 6 (100)             | 92 (40.2)            | NA                      | NA          |
| Kuhn et al. (2007)           | Germany      | Caucasians| NA  | IHC    | NA    | M                 | 0%                        | Tissue | E      | 104 (94.2)     | 90 (0)              | 100 (20)             | NA                      | NA          |
| Paret et al. (2007)          | Germany      | Caucasians| NA  | IHC    | NA    | NA                | 25%                       | Tissue | E      | 100 (94)       | 9 (20)              | 50 (62)              | NA                      | NA          |
| Gosens et al. (2007)         | The Netherlands| Caucasians| NA  | IHC    | 1–4   | M NA              | High                      | Tissue | E      | 109 (64.2)     | 1278 (89.6)         | 305 (49.8)           | Yes                     | NA          |
| Lugli et al. (2010)          | Switzerland  | Caucasians| NA  | IHC    | NA    | M                 | 100%                      | Tissue | High   | 1278 (89.6)    | 305 (49.8)          | 1278 (89.6)         | Yes                     | NA          |
| Kim et al. (2014)            | Korea        | Asians    | NA  | IHC    | 1–4   | M/C               | 90%                       | Tissue | High   | 168 (85.7)     | 50 (6)              | 50 (6)              | Yes                     | NA          |
| Goossens-Beumer et al. (2014)| The Netherlands| Caucasians| NA  | IHC    | 1–4   | M                 | 89%                       | Tissue | High   | 305 (49.8)     | 50 (6)              | 50 (6)              | Yes                     | Yes         |
| Zhou et al. (2015)           | China        | Asians    | NA  | IHC    | 1–4   | C                 | 0%                        | Tissue | E      | 50 (92)        | 50 (6)              | 50 (6)              | No                      | NA          |
| Chai et al. (2015)           | China        | Asians    | NA  | IHC    | 1–3   | C                 | 15%                       | Tissue | E      | 50 (92)        | 90 (5.6)             | 90 (5.6)             | No                      | NA          |
| Kim et al. (2016)            | Korea        | Asians    | NA  | IHC    | 1–3   | M/C               | 95%                       | Tissue | High   | 726 (93)       | 726 (93)             | 726 (93)             | Yes                     | Yes         |

NA: not applicable; E: expression; MA: multivariate analysis; *** stands for a novel chromatographic method (molecular strip) for the detection of PCR-amplified product; IHC: immunohistochemistry; M: membrane; C: cytoplasm.

NA: not applicable; E: expression; MA: multivariate analysis; *** stands for a novel chromatographic method (molecular strip) for the detection of PCR-amplified product; IHC: immunohistochemistry; M: membrane; C: cytoplasm.

Fig. 2. Forest plot showing the relationship between Ep-CAM expression and CRC in cancer vs. controls, CRC vs. normal controls: OR = 96.70, 95% CI = 34.85–268.29, P < 0.001; and CRC vs. benign colonic lesions: OR = 17.07, 95% CI = 0.12–2511.93, P = 0.263.
in Ep-CAM expression (OR = 17.07, 95% CI = 0.12–2511.93, P = 0.265) (Fig. 2).

3.3. Association of Ep-CAM Overexpression with Tumor Differentiation and Clinical Stage of CRC

Ep-CAM overexpression negatively correlated with tumor differentiation and clinical stage (OR = 0.25, 95% CI = 0.11–0.55, P = 0.001; OR = 0.52, 95% CI = 0.28–0.96, P = 0.036; respectively) (Fig. 3) in our analysis of the results from five studies of 3433 CRC patients and four studies with 1308 CRC patients, respectively.

3.4. Association of Ep-CAM Overexpression with Vascular Invasion and Depth of Tumor Invasion of CRC

The results from three studies of 2147 patients with CRC demonstrated a negative correlation between Ep-CAM overexpression and vascular invasion (OR = 0.44, 95% CI = 0.21–0.93, P = 0.032) (Fig. 3).

The pooled OR from five studies of 3429 patients with CRC revealed a trend towards a negative association between Ep-CAM overexpression and depth of tumor invasion (OR = 0.73, 95% CI = 0.51–1.04, P = 0.078) (Fig. 4).

3.5. Association of Ep-CAM Overexpression with Lymph Node Metastasis and Distant Metastasis of CRC

Analysis of the pooled data of five studies of lymph node metastasis with 3393 CRC patients and three studies of distant metastasis with 1348 CRC patients demonstrated that Ep-CAM overexpression negatively correlated with lymph node metastasis and distant metastasis (OR = 0.55, 95% CI = 0.42–0.71, P < 0.001; OR = 0.35, 95% CI = 0.23–0.55, P < 0.001; respectively) (Fig. 4).

3.6. Association of Ep-CAM Overexpression with Tumor Budding and Tumor Location of CRC

The results of a study of 726 CRC patients revealed a negative relationship between Ep-CAM overexpression and tumor budding (OR = 0.18, 95% CI = 0.06–0.50, P = 0.001) (Fig. 4).

The pooled OR from two studies of 1031 CRC patients revealed that Ep-CAM overexpression was similar in colon and rectal cancer (OR = 0.86, 95% CI = 0.56–1.31, P = 0.486) (Fig. 4).

3.7. Association of the Loss of Ep-CAM Expression with the Clinicopathological Features of CRC

Ep-CAM overexpression negatively correlated with the clinicopathological characteristics of CRC patients, including tumor differentiation, tumor stage, vascular invasion, depth of tumor invasion, lymph node metastasis, distant metastasis, and tumor budding. Therefore, we further evaluated whether the loss of Ep-CAM expression positively correlated with these clinicopathological features.

Figs. 5 and 6 show that the loss of Ep-CAM expression positively associated with tumor differentiation, tumor stage, vascular invasion, depth of tumor invasion, lymph node metastasis, distant metastasis, and tumor budding in CRC patients (OR = 4.05, 95% CI = 1.80–9.10, P = 0.001; OR = 1.92, 95% CI = 1.04–3.54, P = 0.036; OR = 2.18, 95% CI = 1.11–4.27, P = 0.024; OR = 1.38, 95% CI = 0.96–1.97, P = 0.078; OR = 1.82, 95% CI = 1.40–2.37, P < 0.001; OR = 2.82, 95% CI = 1.81–4.39, P < 0.001; OR = 4.33, 95% CI = 1.70–11.05, P = 0.001, respectively). No correlation was found between the loss of Ep-CAM expression and tumor location (OR = 1.16, 95% CI = 0.76–1.77, P = 0.486).

3.8. Sensitivity Analysis

Heterogeneity was observed in the comparison of CRC and normal controls, in tumor differentiation, clinical stage, and vascular invasion.

---

**Fig. 3.** Forest plot showing the relationship of Ep-CAM overexpression with some clinicopathological features of CRC, including tumor differentiation: OR = 0.25, 95% CI = 0.11–0.55, P = 0.001; clinical stage: OR = 0.52, 95% CI = 0.28–0.96, P = 0.036; and vascular invasion: OR = 0.44, 95% CI = 0.21–0.93, P = 0.032.
### Fig. 4.

Forest plot showing the association of Ep-CAM overexpression with other clinicopathological features of CRC, including depth of tumor invasion: OR = 0.73, 95% CI = 0.51–1.04, P = 0.078; lymph node metastasis: OR = 0.55, 95% CI = 0.42–0.71, P < 0.001; distant metastasis: OR = 0.35, 95% CI = 0.23–0.55, P < 0.001; tumor budding: OR = 0.18, 95% CI = 0.06–0.50, P = 0.001; and tumor location: OR = 0.86, 95% CI = 0.56–1.31, P = 0.486.

| Study ID | Depth of tumor invasion (pT3-4 vs pT1-2) | OR (95% CI) | Weight |
|----------|----------------------------------------|-------------|--------|
| Went 2006 | 0.59 (0.17, 1.90) | 2.37 |
| Gosens 2007 | 0.81 (0.32, 2.01) | 3.03 |
| Luigi 2010 | 0.94 (0.59, 1.52) | 1.94 |
| Kim 2014 | 0.94 (0.26, 3.46) | 1.33 |
| Kim 2016 | 0.73 (0.51, 1.04) | 21.50 |

| Study ID | Lymph node metastasis (yes vs no) | OR (95% CI) | Weight |
|----------|---------------------------------|-------------|--------|
| Went 2006 | 0.65 (0.24, 1.28) | 4.30 |
| Gosens 2007 | 0.65 (0.45, 0.95) | 19.68 |
| Luigi 2010 | 0.37 (0.20, 0.69) | 9.89 |
| Kim 2014 | 0.55 (0.42, 0.71) | 42.54 |

| Study ID | Distal metastasis (yes vs no) | OR (95% CI) | Weight |
|----------|--------------------------------|-------------|--------|
| Luigi 2010 | 0.51 (0.18, 1.11) | 2.96 |
| Kim 2014 | 0.33 (0.18, 0.63) | 1.93 |
| Kim 2016 | 0.35 (0.25, 0.55) | 14.92 |

| Study ID | Tumor location (colon vs rectum) | OR (95% CI) | Weight |
|----------|---------------------------------|-------------|--------|
| Beumer 2014 | 0.80 (0.53, 1.21) | 6.24 |
| Kim 2016 | 0.86 (0.56, 1.31) | 13.18 |

| Study ID | Tumor budding (yes vs no) | OR (95% CI) | Weight |
|----------|--------------------------|-------------|--------|
| Kim 2016 | 0.18 (0.06, 0.50) | 7.87 |

| Overall | 100.00 |

### Fig. 5.

Forest plot indicating the correlation of loss of Ep-CAM expression with some clinicopathological features of CRC, including tumor differentiation: OR = 4.05, 95% CI = 1.80–9.10, P = 0.001; clinical stage: OR = 1.92, 95% CI = 1.04–3.54, P = 0.036; and vascular invasion: OR = 2.18, 95% CI = 1.11–4.27, P = 0.024.

| Study ID | Tumor differentiation (poor vs well/moderate) | OR (95% CI) | Weight |
|----------|-----------------------------------------------|-------------|--------|
| Went 2006 | 6.14 (2.78, 13.54) | 7.91 |
| Gosens 2007 | 2.50 (1.05, 5.97) | 7.44 |
| Luigi 2010 | 1.53 (0.94, 2.51) | 9.69 |
| Kim 2014 | 4.14 (1.68, 10.19) | 7.27 |
| Kim 2016 | 12.67 (5.81, 28.64) | 7.77 |

| Study ID | Tumor stage (3-4 vs 1-2) | OR (95% CI) | Weight |
|----------|--------------------------|-------------|--------|
| Gosens 2007 | 2.02 (0.87, 4.70) | 7.61 |
| Kim 2014 | 2.98 (1.23, 7.22) | 7.36 |
| Beumer 2014 | 0.99 (0.63, 1.55) | 9.53 |
| Kim 2016 | 2.85 (1.49, 5.44) | 8.78 |

| Study ID | Vascular invasion (yes vs no) | OR (95% CI) | Weight |
|----------|-------------------------------|-------------|--------|
| Luigi 2010 | 1.46 (0.99, 2.15) | 10.25 |
| Kim 2014 | 1.87 (0.75, 4.64) | 7.21 |
| Kim 2016 | 4.02 (2.11, 7.69) | 8.78 |

| Overall | 100.00 |

**NOTE**: Weights are from random effects analysis.
(all \( P < 0.1 \)). We removed the study ([Kuhn et al., 2007]) and recalculated the overall OR (OR = 137.14, 95% CI = 59.32–317.08, \( P = 0.001 \)) in CRC vs. normal controls, which dramatically reduced the heterogeneity \( (P = 0.243) \). We successively removed two studies ([Lugli et al., 2010] and [Kim et al., 2016]) from our correlation analyses between the loss of Ep-CAM expression and tumor differentiation, and the pooled OR was 4.09 (95% CI = 2.42–6.92, \( P < 0.001 \)), with no heterogeneity \( (P = 0.319) \). The combined OR between loss of Ep-CAM expression and tumor stage was 2.62 (95% CI: 1.68–4.08, \( P = 0.001 \)) based on the omission of the study ([Goossens-Beumer et al., 2014]), with no evidence of heterogeneity \( (P = 0.776) \). One study ([Kim et al., 2016]) was removed from the correlation analyses of the loss of Ep-CAM expression with vascular invasion, and the pooled OR did not change substantially \( (OR = 4.33, 95% CI = 1.70–11.05, P = 0.001) \), and tumor location: \( OR = 1.16, 95% CI = 0.76–1.77, P = 0.486 \).

3.9. Prognostic Impact of Ep-CAM Expression in CRC Patients Using Multivariate Analysis

Only two studies reported a multivariate survival analysis of Ep-CAM expression in CRC patients ([Kim et al., 2016]; [Goossens-Beumer et al., 2014]). The loss of Ep-CAM expression correlated with a poor prognosis in disease-specific survival (DSS) and a trend towards a poor prognosis between loss of Ep-CAM expression and a 5-year overall survival (OS) in 305 CRC patients ([Goossens-Beumer et al., 2014]). Multivariate analysis of 725 CRC patients demonstrated that the loss of Ep-CAM expression was an unfavorable prognostic factor in disease-free survival (DFS) \( (HR = 1.57, 95% CI = 1.04–2.39, P = 0.03) \) ([Kim et al., 2016]).

3.10. Diagnostic Capacity of Ep-CAM Expression in CRC vs. Normal Controls

We also evaluated the diagnostic value of Ep-CAM expression as a potential biomarker in the discrimination of CRC patients and normal controls. The pooled sensitivity, specificity and AUC values of Ep-CAM expression were 0.93 (95% CI = 0.90–0.96), 0.90 (95% CI = 0.74–0.97), and 0.94 (95% CI = 0.92–0.96) ([Fig. 7]), respectively, which suggests that Ep-CAM expression exhibited good diagnostic performance in CRC.

4. Discussion

Cancer stem cells (CSCs) are a special subpopulation of cells within a tumor. Ep-CAM overexpression is a CSC marker of tumor cells that closely correlates with tumor progression, including colorectal cancer cell lines ([Liao et al., 2015]). Ep-CAM overexpression is a poor prognostic factor in some cancers, such as breast and gallbladder carcinomas ([Schmidt et al., 2010]; [Varga et al., 2004]), but its overexpression is a favorable prognostic factor in ovarian cancer ([Battista et al., 2014]). The present study found that Ep-CAM was commonly expressed in CRC, and its expression was significantly higher in CRC than in normal controls ([Chai et al., 2015]; [Zhou et al., 2015]; [Paret et al., 2007]; [Kuhn et al., 2007]; [Karanikiotis et al., 2005]). Ep-CAM was slightly less frequently expressed in CRC than in benign lesions ([Zhou et al., 2015]), but its expression level was notably higher in CRC than in benign lesions ([Zhou et al., 2015]). The current results revealed that the frequency of Ep-CAM expression was significantly more common in CRC compared with normal controls, which suggests that Ep-CAM expression is associated with the carcinogenesis of CRC. Ep-CAM expression stimulates cell

Fig. 6. Forest plot indicating the correlation of loss of Ep-CAM expression with other clinico-pathological features of CRC, including depth of tumor invasion: \( OR = 1.38, 95% CI = 0.96–1.97, P = 0.078 \); lymph node metastasis: \( OR = 1.82, 95% CI = 1.40–2.37, P = 0.001 \); distant metastasis: \( OR = 2.82, 95% CI = 1.81–4.39, P < 0.001 \); tumor budding: \( OR = 4.33, 95% CI = 1.70–11.05, P = 0.001 \); and tumor location: \( OR = 1.16, 95% CI = 0.76–1.77, P = 0.486 \).
cogene c-myc, which causes carcinogenic effects (Munz et al., 2004). Differentiation and cell proliferation via up-regulation of the proto-oncogene c-myc, which causes carcinogenic effects (Munz et al., 2004). However, no correlation in Ep-CAM expression was found between CRC and benign colonic lesions because the sample size was small. No association between Ep-CAM expression and DNA mismatch repair protein expression was reported in 218 microsatellite instability (MSI-high) CRCs (Kim et al., 2016).

Ep-CAM overexpression exhibited a high frequency in the present study (88.68%). We analyzed the relationship of Ep-CAM overexpression with the clinicopathological characteristics of CRC patients, including tumor differentiation, tumor stage, vascular invasion, depth of tumor invasion, lymph node metastasis, distant metastasis, and tumor budding. Our findings demonstrated that Ep-CAM overexpression negatively correlated with these clinicopathological characteristics, which indicates that Ep-CAM overexpression was a favorable factor in CRC progression, metastasis, and relapse.

We further investigated whether the loss of Ep-CAM expression was an unfavorable factor in relation to these features. The loss of Ep-CAM expression was significantly associated with tumor differentiation (Kim et al., 2016; Kim et al., 2014; Gosens et al., 2007; Went et al., 2006), and another study demonstrated a positive trend towards an association between the loss of Ep-CAM expression and tumor differentiation (Lugli et al., 2010). An association between the loss of Ep-CAM expression and tumor differentiation, clinical stage, vascular invasion, lymph node metastasis, distant metastasis, and tumor budding. We also found that a loss of Ep-CAM expression exhibited a positive trend with depth of tumor invasion (OR = 1.38, 95% CI = 0.96–1.97, P = 0.078). These analyses indicate that loss of Ep-CAM expression plays a crucial role in CRC progression, metastasis, and relapse.

Loss of Ep-CAM expression with multivariate analysis was a poor prognostic factor in disease-specific survival (DSS) (Goossens-Beumer et al., 2014), 5-year overall survival (OS) (Goossens-Beumer et al., 2014), and disease-free survival (DFS) (Kim et al., 2016), which suggests that loss of Ep-CAM expression may be a potential prognostic biomarker.

Some studies demonstrated the use of CSCs as a marker for the detection and diagnosis of cancer (Takaishi et al., 2008; Yang et al., 2008; Nagrath et al., 2007). We evaluated whether Ep-CAM expression was a useful diagnostic biomarker for CRC. A comparison of CRC and normal controls demonstrated combined sensitivity, specificity and AUC values of Ep-CAM expression of 0.93, 0.90, and 0.94, respectively, which was very good (all values ≥0.9). These results suggest that Ep-CAM expression exhibits good diagnostic capacity as a promising molecular biomarker for CRC diagnosis. The importance of Ep-CAM was validated in an Ep-CAM-based assay, the CellSearch® System, which is the only Food and Drug Administration (FDA)-approved assay for the enrichment and detection of circulating tumor cells (CTCs) (Cohen et al., 2008). We also found that the detection of Ep-CAM expression in the blood exhibited a sensitivity of 96.3% and specificity of 100% (Karanikiotis et al., 2005), which indicates that the detection rate of Ep-CAM-expressing circulating tumor cells may be higher in blood samples and serve as a potential noninvasive marker. Additional large-scale and well-designed prospective studies are essential to further confirm the diagnostic effect of Ep-CAM expression in clinical applications, especially the use of blood samples.

There was evidence of heterogeneity in CRC vs. normal controls in tumor differentiation, clinical stage, and vascular invasion (all P < 0.1). We removed one study (Kuhn et al., 2007) in cancer vs. normal controls, two studies (Lugli et al., 2010) and (Kim et al., 2016) for tumor differentiation, the study (Goossens-Beumer et al., 2014) for tumor stage, and the study (Kim et al., 2016) for vascular invasion. The pooled OR remained significant with no evidence of heterogeneity, which indicated the stability and reliability of our results. The reasons for the heterogeneity were not clear, perhaps because of the use of inappropriate or different conditions in immunohistochemistry (IHC) methods, which may have led to the observed bias.

5. Limitations

This meta-analysis has some limitations. First, our study primarily included only Asian and Caucasian populations, and data on other populations, such as African populations, were lacking. Second, the analysis included only available articles published in English. Publications in other languages were excluded due to incomprehensible information, which may result in selection bias. Third, only two studies with small populations were examined to assess the correlation between CRC and benign lesions. Finally, only one study involving blood samples was analyzed in the present meta-analysis, and more studies with large sample sizes are essential to further validate the diagnostic value of Ep-CAM expression.
6. Conclusions

Our findings suggest that Ep-CAM expression is notably higher in CRC patients than in normal controls. Loss of Ep-CAM expression correlated with tumor differentiation, tumor stage, vascular invasion, depth of tumor invasion, lymph node metastasis, distant metastasis, and tumor budding in CRC. Loss of Ep-CAM expression may be a poor prognostic factor of CRC in DFS, DSS and OS. The use of Ep-CAM expression may be a potential biomarker for the diagnosis of CRC patients in the clinical setting. However, more clinical prospective studies using large populations with CRC are necessary to further confirm the diagnostic and prognostic effects.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ebiom.2017.05.025.

Authors’ Contributions

Susu Han, Fanggeng Hou and Wen Li contributed to the conception and design of this research. Susu Han, Shaoqi Zong and Qi Shi contributed to the drafting of the article and final approval of the submitted version. Susu Han, Shaoqi Zong, Qi Shi, Hongjia Li, Shanshan Liu, Wei Yang, Wen Li, and Fanggeng Hou contributed to data analyses and interpretation and completion of the figures and tables. All authors read and approved the final manuscript.

Competing Financial Interests

All authors declare they have no competing financial interests.

Ethical Review from Patients

Our study was not primary research involving human samples, but rather a secondary analysis of human subject data published in the public domain.

Acknowledgments and Funding

This research was supported by grants from the Natural Science Foundation of China (81473624). The sponsor had no role in the design, study collection, data analysis, data interpretation, or writing of the report.

References

Aranda, E., Aparicio, J., Alonso, V., Garcia-Albeniz, X., Garcia-Alfonso, P., Salazar, R., Valladares, M., Vera, R., Villate, J.M., Garcia-Carbonero, R., 2015. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin. Transl. Oncol. 17, 972–981.
Balzar, M., Winter, M.J., De Boer, C.J., Litvivin, S.V., 1999. The biology of the 17–1A antigen (Ep-CAM). J. Mol. Med. (Berl.) 77, 699–712.
Bartzi, M.J., Cotarelo, C., Jakobi, S., Steetskamp, J., Makris, G., Sicking, I., Weyer, V., 2014. Clinical prognostic value of combined analysis of ALDH1, Survival, and Ep-CAM expression in colorectal cancer. Br. J. Cancer 110, 2955–2964.
Gossens, M.J., Van Kempen, L.C., Van De Velde, C.J., Van Krieken, J.H., Nagtegaal, I.D., 2007. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod. Pathol. 20, 221–232.

Gupta, P.B., Chaffer, C.L., Weinberg, R.A., 2009. Cancer stem cells: mirage or reality? Nat. Med. 15, 1010–1012.
Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., 2003. Measuring inconsistency in meta-analyses. BMJ 327, 557–560.

Jones, C.M., Athanasiou, T., 2005. Summary receiver operating characteristic curve analy-
sis techniques in the evaluation of diagnostic tests. Ann. Thorac. Surg. 79, 16–20.
Karanikoti, C., Skladas, I., Karina, M., Georgakopoulos, S., Georgakopoulos, E., Fountzilas, G., 2005. A novel chromatographic method for Ep-CAM mRNA detection in peripheral blood and bone marrow of patients with metastatic colorectal cancer. Anticancer Res. 25, 1635–1639.
Kim, J.H., Eae, J.M., Kim, J.I., Rheu, Y.Y., Kim, Y., Cho, N.Y., Lee, H.S., Chang, M.S., Kang, G.H., 2014. Differential features of microsatellite-unstable colorectal carcinomas depend-
ing on EPICAM expression status. Korean J. Pathol. 48, 278–282.
Kim, J.H., Eae, J.M., Song, Y.S., Cho, N.Y., Lee, H.S., Kang, G.H., 2016. Clinicopathologic, mo-
lecular, and prognostic implications of the loss of EPICAM expression in colorectal carci-
noma. Oncotarget 7, 13372–13387.
Kuhn, S., Koch, M., Nebel, T., Ludwine, M., Antoniolev, D., Klingbeil, P., Hildebrand, D., Moldenhauer, G., Hanger, L., Franken, W.V., Weitz, J., Zoller, M., 2007. A complex of Ep-CAM, claudin-7, CD44 variant isoforms, and tenascins promotes colorectal cancer progression. Mol. Cell Res. 5, 553–567.
Lau, J., Ioannidis, J.P., Schmid, C.H., 1997. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820–826.
Liao, M.Y., Kuo, M.Y., Lu, T.Y., Wang, Y.P., Wu, H.C., 2015. Generation of an anti-EpCAM an-
tibody and epigenetic regulation of Ep-CAM in colorectal cancer. Int. J. Oncol. 46, 1788–1800.
Linonen, A.J., Wójcierowski, J., Wu, S.A., Pyrc, J.J., Ross, A.H., Dietzschold, B., Speicher, D., Koprowski, H., 1989. Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GAST33. Proc. Natl. Acad. Sci. U. S. A. 86, 27–31.
Litvivin, S.V., Baker, H.A., Gourevitch, M.M., Velders, M.P., Warmaar, S.O., 1994. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial-cell-cell adhesion. Cell Adhes. Commun. 2, 417–428.

Lugli, A., Jezi, G., Hostettler, I., Muraro, M.G., Mele, V., Tornillo, L., Caraglia, V., Spagnoli, G., Terracciano, L., Zlobec, L., 2010. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44, EpCAM, and ALDH1 in colorectal cancer. Br. J. Cancer 103, 382–390.

Maetzel, D., Denzel, S., Mack, B., Canis, M., West, P., Benik, M., Kiei, C., Papior, P., Baeruerle, P.A., Munz, M., Gries, O., 2009. Nuclear signalling by tumour-associated antigen EpCAM in NEC. Nat. Cell Biol. 11, 162–171.

Majumdar, A., Curley, S.A., Wu, X., Brown, P., Hwang, J.P., Shetty, K., Yao, X.Z., He, A.R., Li, S., Katz, L., Farci, P., Mishra, L., 2012. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 9, 530–539.

Moeller, D., Libe, R., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2355.
Moldenhauer, G., Salmink, A.V., Lutgau, S., Herr, I., Anderl, J., Faulstich, H., 2012. Thera-
potential of amanitin-conjugated epithelial cell adhesion molecule monoo-
clonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 104, 622–634.

Morel, A.P., Liefers, M., Thomas, C., Hinkal, G., Anseube, P., Suisseux, A., 2008. Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS One, 3, e826.

Mosliots, S., Markovic, K., Frodin, J.E., Virving, L., Magnusson, C.G., Steinitz, M., Fagerberg, J., Mellstedt, H., 2004. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-limited Ep-CAM epitopes in colon cancer patients. Clin. Cancer Res. 10, 5391–5402.

Munz, M., Kiei, C., Mack, B., Schmitz, R., Zeidler, R., Gries, O., 2004. The carcinoma-associ-
ated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23, 5748–5758.

Nagras, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., Smith, M.R., Kwak, E.L., Dignamart, S., Muzinskianys, A., Ryan, P., Balis, U.J., Tompkins, R.G., Haber, D.A., 2007. Isolation of rare circulating tumour cells in cancer patients by micro-
chip technology. Nature 450, 1235–1239.

Nguyen, L.V., Vanner, R., Dirks, P., Caves, J.J., 2012. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133–143.

Nicolazzo, C., Massimi, I., Lotti, L.V., Vespa, S., Raimondi, C., Pulcini, M.F., Gradilone, A., Gazzaniga, P., 2015. Impact of chronic exposure to bevacizumab on Ep-CAM-based de-
tecting rare circulating tumor cells. Clin. J. Cancer Res. 27, 491–496.

Paret, C., Hildebrand, D., Weitz, J., Kopp-Schneider, A., Kuhn, A., Beer, M., Hautmann, R., Zoller, M., 2007. C4.4A as a candidate marker in the diagnosis of colorectal cancer. Br. J. Cancer 97, 1146–1156.

Pattana, K., 2016. Colorectal cancer: targeting the root of colorectal cancer—eliminating cancer stem cells. Nat. Rev. Gastroenterol. Hepatol. 13, 2.
Raimondi, C., Nicolazzo, C., Gradilone, A., 2015. Circulating tumor cells isolation: the “post-EpCAM era”. Chin. J. Cancer Res. 27, 461–470.

Reitsma, J.B., Glas, A.S., Rutjes, A.W., Scholten, R.J., Bossuyt, P.M., Zwinderman, A.H., 2005. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 58, 982–990.

Sampetrean, O., Saya, H., 2013. Characteristics of glioma stem cells. Brain Tumor Pathol 30, 209–214.

Schmidt, M., Scheulen, M.E., Dittrich, C., Obrist, P., Marschner, N., Dirix, L., Schmidt, M., Ruttinger, D., Schulier, M., Reinhardt, C., Awada, A., 2010. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann. Oncol. 21, 275–282.

Subramanian, N., Kanwar, J.R., Kanwar, R.K., Sreemanthula, J., Biswas, J., Khetan, V., Krishnakumar, S., 2015. EpCAM aptamer-siRNA chimera targets and regresses epithelial cancer. Plui5 One 10, e012407.

Takaishi, S., Okamura, T., Wang, T.C., 2008. Gastric cancer stem cells. J. Clin. Oncol. 26, 2876–2882.

Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., 2015. Global cancer statistics. 2012. CA Cancer J. Clin. 65, 87–108.

Van Cutsem, E., Nordlinger, B., Cervantes, A., GROUP, E. G. W. 2010. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann. Oncol. 21 (Suppl. 5), v93–v97.